Covid Vaccination Argentina

gracielle

Registered
Updated Oct. 27, 2021

29 October 2021
New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

 

gracielle

Registered
3 November 2021
WHO approved on Wednesday the emergency use of the vaccine against the coronavirus Covaxin, from the Indian laboratory Bharat Biotech. Province of BA expects 15M doses to arrive from India. This vaccine, which has an efficacy of 78%, is recommended for all persons 18 years of age and older. It requires two doses four weeks apart and "is particularly suitable for resource-poor countries because it can be easily stored," the WHO statement said. It is the first vaccine developed and manufactured entirely in India to be approved by the UN organization....Once they arrive in the province, they will be offered to the national gov't so that "they can be distributed among all the provinces of Argentina", said Governor Axel Kicillof.

3 November 2021

The details of Covaxin, the new vaccine approved by the WHO. In Argentina it has not yet been approved by ANMAT....
 
Last edited:

Somewhereinba

Registered
Updated Oct. 27, 2021

29 October 2021
New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

Not sure why anyone would trust a study from the CDC regarding vaccines. Does anyone really think they would come out and say that natural immunity offers better and longer protection than the vaccine as the Israel study proved? Sorry but they are extremely biased - their hand is literally in the jar they are feeding people.
 
  • Like
Reactions: Moe

lunar

Registered
Does anyone really think they would come out and say that natural immunity offers better and longer protection than the vaccine as the Israel study proved?
Was this revolutionary study conducted before or after Israel vaccinated the entire population?

Every self-respecting conspiracy theorist knows that all people are naturally immune to the coronavirus, and this whole story about the pandemic was invented by CDC, NIH, FDA and other government organizations.
 

gracielle

Registered
27 Oct 2021

From: Medicines and Healthcare products Regulatory Agency. Published 4 Nov 2021
 

cuando_volverá

Registered
Was this revolutionary study conducted before or after Israel vaccinated the entire population?

Every self-respecting conspiracy theorist knows that all people are naturally immune to the coronavirus, and this whole story about the pandemic was invented by CDC, NIH, FDA and other government organizations.
Not really sure what your point is. This conspiracy website suggests that the vaccine may not be very effective:


The article is from August.
 
  • Like
Reactions: Moe

gracielle

Registered
4 Nov 2021 by Pablo Sigal
Covid pill (Lagevrio/molnupiravir)....Clarin has learned from pharmaceutical industry sources, the local subsidiary of the Merck Sharpe & Dohme laboratory, which produces this new drug, is working with ANMAT and the Ministry of Health so that Argentina can have access to this pill in the shortest possible time. UK approved the drug for patients who have at least one risk factor (obesity, diabetes, hypertension and renal failure), although each regulatory agency can decide whether to restrict it to that population or extend it to those patients who do not have comorbidities. The clinical trial, which had 55% of volunteers in LatAm of which Argentina took part, showed a 50% reduction in the risk of hospitalization. In addition, in the group that took the pill, none died and in the group that received the placebo, there were 8 fatalities.

The EMA said in the last few hours that it is seeking to accelerate the study it launched last week on this drug, with a view to authorizing its marketing. "We will try to accelerate our assessment in order to obtain authorization in the shortest possible time," said Marco Cavaleri, head of the EMA's vaccination strategy. For now, there is no exact date for the antiviral to be given the green light in Europe. It is also expected that the US FDA will give its verdict shortly. These two instances would be key to speed up the authorization process in Argentina as well....

....Although it was reported on Thursday that Argentina could be the producer of a generic of this antiviral, Bugarin explained that "this possibility exists only for countries considered by the World Bank as low and medium resource countries, a list in which Argentina is not included"....Clarín also consulted sources from the Ministry of Health to find out what are the chances that Argentines will have access to this drug in the short term. The answer was cautious: "It is an antiviral that has been approved only in the UK for the time being. We are evaluating it. When we have information we will communicate it", they said.
 

gracielle

Registered
5 Nov 2021 by Fabiola Czubaj
Against the official announcement: the Gov't applied Sinopharm to children from 3 to 11 years of age before China, the producer country....There were 500 million "children and adolescents" who were being vaccinated with Sinopharm in China, according to the National Minister of Health, Carla Vizzotti, when the Gov't announced on October 1 that it would imitate the strategy for children between 3 and 11 years of age. Thus, with the decision to allocate a stock of 10M doses to children, a campaign which effectively started on October 12 in the subgroup with comorbidities, Argentina was almost one month ahead of China, the producer country.

However it was only last Friday that China's National Health Commission announced that it had began to apply the dose to children under 12 the previous day due to the increase in the number of infections, having approved the use in June. Argentina became the second country in the world to test this vaccine against Covid in this age group. It was last week that Bahrain's National Medical Commission to Combat Coronavirus reported approval for use of Sinopharm for that population. The UAE was the first country to license Sinopharm between the ages of 3 and 11 with as yet unpublished data from a Phase III study of 900 boys, ages 3 to 17, with no comorbidities.
 
Top